Estimating Transition Probabilities from Published Evidence: A Tutorial for Decision Modelers.

abstract：OBJECTIVE:To decompose drug spending in Sweden between the years 1990 and 2000. This paper updates a previous study, which looked at the period 1990-1995, by providing an additional 5 years of data (1995-2000) and extending the previous analysis in a number of ways. METHODS:The paper builds on the earlier work that sh...

journal_title：PharmacoEconomics

authors： Gerdtham UG,Lundin D

更新日期：2004-01-01 00:00:00

abstract：:Epilepsy is a chronic condition with numerous social and psychological consequences. This work aimed to review available data on epilepsy and the impact of surgical and pharmaceutical treatments on the quality of life in adults and children. Research on quality of life in epilepsy is characterised by a wide and fragme...

journal_title：PharmacoEconomics

authors： Berto P

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:The measurement and valuation of health-related quality of life for and by young people are increasingly important, yet research on the impact of study perspective and validity of preferences obtained from young populations remains limited. OBJECTIVE:The objective of this study was to evaluate the feasibili...

journal_title：PharmacoEconomics

authors： Dalziel K,Catchpool M,García-Lorenzo B,Gorostiza I,Norman R,Rivero-Arias O

更新日期：2020-05-01 00:00:00

abstract：OBJECTIVE:A cost-effectiveness analysis of oral capecitabine versus intravenous bolus 5-fluorouracil/l-leucovorin (FU/LV) as adjuvant therapy in patients with stage 3 colon cancer was performed from a Japanese healthcare payer perspective. METHODS:Adjuvant therapy comprised 24 weeks of treatment with either oral capec...

journal_title：PharmacoEconomics

authors： Shiroiwa T,Fukuda T,Shimozuma K,Ohashi Y,Tsutani K

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND:While drotrecogin alfa (activated) was shown to decrease absolute 28-day mortality by 6.1% in patients with severe sepsis in the Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study, no mortality benefit was observed in the subset of patients with only one organ system failure. C...

journal_title：PharmacoEconomics

authors： Betancourt M,McKinnon PS,Massanari RM,Kanji S,Bach D,Devlin JW

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:There is evidence that the earlier a patient reaches hospital and receives thrombolysis, the better the outcome. The GREAT (Grampian Region Early Anistreplase Trial) directly addressed the issue of early thrombolysis by evaluating, in a randomised controlled trial, the efficacy of thrombolysis in the communi...

journal_title：PharmacoEconomics

authors： Vale L,Steffens H,Donaldson C

更新日期：2004-01-01 00:00:00

abstract：:The pharmaceutical industry's core business is the innovation, development and marketing of new drugs. Pharmacogenetic (PG) testing and technology has the potential to increase a drug's value in many ways. A critical issue for the industry is whether products in development should be teamed with genetic tests that cou...

journal_title：PharmacoEconomics

authors： Vernon JA,Johnson SJ,Hughen WK,Trujillo A

更新日期：2006-01-01 00:00:00

abstract：OBJECTIVE:To explore whether the National Institute for Health and Clinical Excellence (NICE) takes account of concerns other than just incremental cost effectiveness in commissioning healthcare services. METHOD:A stated preference binary choice experiment was used to explore the preferences of members of NICE's Appra...

journal_title：PharmacoEconomics

authors： Tappenden P,Brazier J,Ratcliffe J,Chilcott J

更新日期：2007-01-01 00:00:00

abstract：INTRODUCTION:Recent clinical trial results have demonstrated that, in patients with type 2 diabetes, second-line treatment of rosiglitazone in combination with metformin can lead to significant improvements in the control of fasting plasma glucose/ glycosylated haemoglobin A1c (HbA1c) after the failure of metformin mon...

journal_title：PharmacoEconomics

authors： Beale S,Bagust A,Shearer AT,Martin A,Hulme L

更新日期：2006-01-01 00:00:00

abstract：OBJECTIVE:To assess the economic efficiency of meloxicam, a cyclo-oxygenase (COX)-2 selective inhibitor, versus diclofenac and piroxicam in the UK for the treatment of patients with osteoarthritis and the impact on the NHS budget of substituting nonselective NSAIDs with meloxicam. Methods and perspective: A decision an...

journal_title：PharmacoEconomics

authors： Tavakoli M

更新日期：2003-01-01 00:00:00

abstract：:In this paper we consider the evolving American healthcare landscape and what it means for the use of economic evaluation of health interventions. We emphasise that use of economic evaluation in the US is unlikely to follow the European, Canadian or Australian models, which use cost effectiveness openly and explicitly...

journal_title：PharmacoEconomics

authors： Neumann PJ,Sullivan SD

更新日期：2006-01-01 00:00:00

abstract：:Nonsteroidal anti-inflammatory drugs (NSAIDs) are widely used for the relief of the symptoms of osteoarthritis (OA), rheumatoid arthritis (RA), sprains and strains, sports injuries and menstrual disorders, and have a small role in the management of patent ductus arteriosus in the neonate. In patients with RA, symptom...

journal_title：PharmacoEconomics

authors： Wynne HA,Campbell M

更新日期：1993-02-01 00:00:00

abstract：:Scientific reviewing methods were applied to economic studies of influenza vaccination, and an economic model of influenza vaccination was developed from these primary sources. Issues arising from the secondary literature review include the quality of evidence on the effectiveness of the vaccines, the absence of a tra...

journal_title：PharmacoEconomics

authors： Jefferson T,Demicheli V

更新日期：1996-01-01 00:00:00

abstract：:Proper economic evaluation involves comparative analysis of alternative courses of action in terms of both costs and outcome. This is difficult for general anaesthesia as there are few alternatives and measurement of outcome is difficult to define. All that is generally available is a cost description of different a...

journal_title：PharmacoEconomics

authors： Rhodes SP,Ridley S

更新日期：1993-02-01 00:00:00

abstract：BACKGROUND:Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory lung disease associated with increasing morbidity and mortality and an economic burden that stretches beyond the patient to healthcare systems. Avoiding exacerbations and subsequent hospitalizations is an important clinical aim and ca...

journal_title：PharmacoEconomics

authors： Mittmann N,Hernandez P,Mellström C,Brannman L,Welte T

更新日期：2011-05-01 00:00:00

abstract：:Venetoclax is licensed to treat relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL). As part of the Single Technology Appraisal (STA) ID944, the National Institute for Health and Care Excellence (NICE) invited AbbVie, the manufacturer, to submit evidence on the use of venetoclax, within its licensed indic...

journal_title：PharmacoEconomics

authors： Mistry H,Nduka C,Connock M,Colquitt J,Mantopoulos T,Loveman E,Walewska R,Mason J

更新日期：2018-04-01 00:00:00

abstract：:Until a few years ago, griseofulvin and ketoconazole were the only 2 oral agents available for the treatment of dermatophyte onychomycosis of the toenails. With the availability of the newer antifungal agents, such as itraconazole, terbinafine and fluconazole, the armamentarium of drugs available to treat onychomycosi...

journal_title：PharmacoEconomics

authors： Gupta AK

更新日期：1998-02-01 00:00:00

abstract：:To review and critically evaluate published cost-utility analyses (CUAs) pertaining to pharmaceuticals for the past 3 decades. We examined data from the Tufts Medical Center Cost-Effectiveness Analysis Registry (www.cearegistry.org), which contains detailed information on English-language CUAs and their ratios (in $US...

journal_title：PharmacoEconomics

authors： Neumann PJ,Fang CH,Cohen JT

更新日期：2009-01-01 00:00:00

abstract：OBJECTIVE:To estimate the annual direct cost of managing erectile dysfunction (ED) to the UK National Health Service (NHS) and to examine the impact of the introduction of sildenafil in 1998 and Schedule 11 restrictions in 1999. DESIGN:A prevalence-based cost-of-illness approach was used. The period 1997 to 2000 was c...

journal_title：PharmacoEconomics

authors： Wilson EC,McKeen ES,Scuffham PA,Brown MC,Wylie K,Hackett G

更新日期：2002-01-01 00:00:00

abstract：:Health economic modelling studies are of interest to many parties with different responsibilities and diverging interests. Therefore, it is obvious that recognising the relevance of statistical uncertainty and dealing with it appropriately are required to obtain unbiased results from health economic modelling studies,...

journal_title：PharmacoEconomics

authors： Nuijten MJ

更新日期：2004-01-01 00:00:00

abstract：:The pharmacoeconomics of the low molecular weight heparin (LMWH) enoxaparin in the prophylaxis and treatment of venous thromboembolism have mostly been investigated in cost-effectiveness studies that estimated direct costs associated with treatment, using decision analyses and clinical outcome data from randomised con...

journal_title：PharmacoEconomics

authors： Bergqvist D

更新日期：2002-01-01 00:00:00

abstract：BACKGROUND:International phase III studies (CHIB 201 and 352) showed that basiliximab, a high affinity chimeric monoclonal antibody interleukin-2 receptor antagonist, is highly effective in preventing acute rejection when used as immunoprophylaxis in patients receiving cyclosporin (Neoral). We conducted a cost evaluati...

journal_title：PharmacoEconomics

authors： Hasegawa T,Imai H,Miki S

更新日期：2003-01-01 00:00:00

abstract：BACKGROUND:Swedish formulary committees are expected to influence prescribing practice by establishing and issuing drug lists and clinical practice guidelines, particularly now that financial responsibility for prescription drugs has been transferred from the national to the county council level. OBJECTIVE:The purpose...

journal_title：PharmacoEconomics

authors： Anell A,Svarvar P

更新日期：2000-02-01 00:00:00

abstract：:Recombinant human erythropoietin (rHuEpo) has been increasingly used in preterm infants in the last 3 to 4 years. Recent studies have indicated a reduction in blood transfusion requirements in infants receiving rHuEpo. No significant adverse effects have emerged, apart from iron deficiency (if iron supplementation is ...

journal_title：PharmacoEconomics

authors： Meyer MP

更新日期：1997-10-01 00:00:00

abstract：:Although decision making about what drugs to include in an institutional formulary appears to lend itself readily to quantitative techniques such as decision analysis and cost-benefit analysis, a review of the literature reveals that very little has been published in this area. Several of the published decision analy...

journal_title：PharmacoEconomics

authors： Schechter CB

更新日期：1993-06-01 00:00:00

abstract：:The purpose of this study was to estimate the direct and indirect costs of alcoholism in the Federal Republic of Germany. Direct costs comprised treatment costs, while indirect costs consisted mainly of costs incurred as a result of work time lost, as well as costs related to premature retirement and premature mortali...

journal_title：PharmacoEconomics

authors： Brecht JG,Poldrugo F,Schädlich PK

更新日期：1996-11-01 00:00:00

abstract：:The recent multinational, randomised, prospective studies Clopidogrel in Unstable Angina to Prevent Recurrent Events (CURE), Percutaneous Coronary Intervention substudy of CURE (PCI-CURE) and Clopidogrel for the Reduction of Events During Observation (CREDO) have demonstrated the clinical efficacy and safety of clopid...

journal_title：PharmacoEconomics

authors： Weintraub W,Jönsson B,Bertrand M

更新日期：2004-01-01 00:00:00

abstract：:There are insufficient resources in the UK to fund all new technologies and new indications approved by the National Institute for Health and Clinical Excellence (NICE). Diverting funding from existing sources will have a detrimental effect on the provision of other priority services. The UK Office of Fair Trading (OF...

journal_title：PharmacoEconomics

authors： Godman B,Haycox A,Schwabe U,Joppi R,Garattini S

更新日期：2008-01-01 00:00:00

abstract：BACKGROUND:Interventions in health care often not only have an effect on patients, but also on their informal caregivers. Caregiving can have a profound impact on the health and wellbeing of carers. Ignoring these spillovers in economic evaluations risks labelling interventions mistakenly as cost-effective, at the expe...

journal_title：PharmacoEconomics

authors： Hoefman RJ,van Exel J,Brouwer WBF

更新日期：2019-04-01 00:00:00

abstract：:In this article, we model the behavior of a pharmaceutical firm that has marketing authorization for a new therapy believed to be a candidate for personalized use in a subset of patients, but that lacks information as to why a response is seen only in some patients. We characterize the optimal outcome-based reimbursem...

journal_title：PharmacoEconomics

authors： Antoñanzas F,Rodríguez-Ibeas R,Juárez-Castelló CA

更新日期：2018-07-01 00:00:00